← Leaderboards
Taixing Cui
University Of Missouri-Columbia
$3,824,823
Attributed
$4,807,292
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $642.7K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,807,292 · 6
VA$0 · 1
By mechanism
R01$3,443,853 · 2
P20$839,814 · 2
R21$367,125 · 1
R03$156,500 · 1
I01$0 · 1
Top collaborators
- Xuejun Wang4 shared
- John F Eberth2 shared
- Igor B Roninson2 shared
- Chuanbing Tang2 shared
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingLinkIn VivoSignal TransductionPathway InteractionsPilot ProjectsKnock-OutProteinsFunctional DisorderHeart FailureCardiac MyocytesHeart DiseasesCardiacGenesHeartFailureMouse ModelPhenotypeRegulationProgramsIn VitroOverexpressionUbiquitin
Grant awards (22)
Metabolic control of vascular smooth muscle cell plasticity$464,679
R01 · FY2025 · HL · contact PI
Metabolic control of vascular smooth muscle cell plasticity$442,568
R01 · FY2024 · HL · contact PI
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2024 · VA · contact PI
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2024 · VA · contact PI
Metabolic control of vascular smooth muscle cell plasticity$486,178
R01 · FY2023 · HL · contact PI
Cyclin-dependent kinase (CDK)19-mediated vein graft intimal hyperplasia$156,500
R03 · FY2023 · TR · contact PI
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2023 · VA · contact PI
Metabolic control of vascular smooth muscle cell plasticity$636,178
R01 · FY2022 · HL · contact PI
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2022 · VA · contact PI
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2021 · VA · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2020 · HL
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure$0
I01 · FY2020 · VA · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2019 · HL
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$350,625
R01 · FY2018 · HL
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries$200,250
R21 · FY2018 · EB · contact PI
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation$362,375
R01 · FY2017 · HL
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries$166,875
R21 · FY2017 · EB · contact PI
American Ginseng-mediated Autophagy and Suppression of Inflammation (Project 3)$205,500
P20 · FY2016 · GM · contact PI
American Ginseng-mediated Autophagy and Suppression of Inflammation (Project 3)$205,500
P20 · FY2014 · GM · contact PI
American Ginseng-mediated Autophagy and Suppression of Inflammation (Project 3)$198,308
P20 · FY2013 · GM · contact PI
American Ginseng-mediated Autophagy and Suppression of Inflammation (Project 3)$205,500
P20 · FY2012 · GM · contact PI
UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1 (UCH-L1) AND VASCULAR LESION FORMATION$25,006
P20 · FY2010 · RR · contact PI